Artelo Biosciences, Inc.
ARTLNASDAQHealthcare● Active
$1.33
$-0.05(-3.62%)
Market Cap$3103836
P/E Ratio—
52W High$85.8
52W Low$1.19
Artelo Biosciences, Inc. (ARTL) Earnings: Dates, EPS & Revenue History
Quarterly EPS vs. estimates, revenue surprises, next earnings date, and analyst consensus.
ARTL · earnings · updated Jun 8, 2026
Latest Earnings
Q2 FY2026Report Date: May 14, 2026EPS Actual
-$4.00
Est. -$0.78 · -412.8%
Revenue
—
Fiscal Period
Q2 FY2026
FY ends December
Report Date
May 14, 2026
After Market Close
▼ Miss EPS
ARTL reports quarterly as a NASDAQ-listed Biotechnology company. Fiscal year ends in December. Data: FMP · Updated hourly.
Next Earnings Date
Days Away
85
days
Expected Date
Sep 1, 2026
Fiscal Period
Q3 FY2026
Release Time
◌ Time TBD (Unconfirmed)EPS Est.
$0.21
Rev. $0.66B
Days Away85
Expected DateSep 1, 2026
Fiscal PeriodQ3 FY2026
Release TimeTime TBD (Unconfirmed)
EPS Est.$0.21
Rev. Est.$0.66B
EPS & Revenue vs. Estimates
Actual (Beat)
Actual (Miss)
Estimated
Earnings History
| Period | Report Date | EPS Est. | EPS Actual | EPS Surpr. | Revenue | Rev. Est. | Rev. Surpr. |
|---|---|---|---|---|---|---|---|
| ◌ Q3 FY2026 | Aug 12, 2026 | -$0.72 | — | — | — | — | — |
| ▼ Q2 FY2026 | May 14, 2026 | -$0.78 | -$4.00 | -412.8% | — | — | — |
| ▼ Q1 FY2026 | Feb 24, 2026 | -$4.71 | -$6.66 | -41.4% | — | — | — |
| ▼ Q4 FY2025 | Nov 12, 2025 | -$0.82 | -$3.97 | -384.1% | — | — | — |
| ▼ Q3 FY2025 | Aug 13, 2025 | -$4.19 | -$5.61 | -33.9% | — | — | — |
| ▼ Q2 FY2025 | May 13, 2025 | -$0.80 | -$4.32 | -440.1% | — | — | — |
| ▼ Q1 FY2025 | Mar 3, 2025 | -$2.62 | -$7.02 | -167.9% | — | — | — |
| ▲ Q4 FY2024 | Nov 12, 2024 | -$4.75 | -$2.10 | +55.8% | — | — | — |
Q3 FY2026
Aug 12, 2026
EPS Actual
—
EPS Est.
-$0.72
EPS Surpr.
—
Revenue
—
Q2 FY2026
May 14, 2026Miss
EPS Actual
-$4.00
EPS Est.
-$0.78
EPS Surpr.
-412.8%
Revenue
—
Q1 FY2026
Feb 24, 2026Miss
EPS Actual
-$6.66
EPS Est.
-$4.71
EPS Surpr.
-41.4%
Revenue
—
Q4 FY2025
Nov 12, 2025Miss
EPS Actual
-$3.97
EPS Est.
-$0.82
EPS Surpr.
-384.1%
Revenue
—
Q3 FY2025
Aug 13, 2025Miss
EPS Actual
-$5.61
EPS Est.
-$4.19
EPS Surpr.
-33.9%
Revenue
—
Q2 FY2025
May 13, 2025Miss
EPS Actual
-$4.32
EPS Est.
-$0.80
EPS Surpr.
-440.1%
Revenue
—
Q1 FY2025
Mar 3, 2025Miss
EPS Actual
-$7.02
EPS Est.
-$2.62
EPS Surpr.
-167.9%
Revenue
—
Q4 FY2024
Nov 12, 2024Beat
EPS Actual
-$2.10
EPS Est.
-$4.75
EPS Surpr.
+55.8%
Revenue
—
Analyst Estimates
Limited analyst coverage (fewer than 3 analysts). Estimates may not reflect market consensus.
EPS Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q4 FY2028 | $-0.49 | $-0.49 | $-0.49 | 1 |
| Q3 FY2028 | $-0.44 | $-0.44 | $-0.44 | 1 |
| Q2 FY2028 | $-0.41 | $-0.41 | $-0.41 | 1 |
| Q1 FY2028 | $-0.43 | $-0.43 | $-0.43 | 1 |
| Q4 FY2027 | $-0.48 | $-0.48 | $-0.48 | 1 |
| Q3 FY2027 | $-0.43 | $-0.43 | $-0.43 | 1 |
Revenue Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q4 FY2028 | $0.0B | $0.0B | $0.0B | 0 |
| Q3 FY2028 | $0.0B | $0.0B | $0.0B | 0 |
| Q2 FY2028 | $0.0B | $0.0B | $0.0B | 0 |
| Q1 FY2028 | $0.0B | $0.0B | $0.0B | 0 |
| Q4 FY2027 | $0.0B | $0.0B | $0.0B | 0 |
| Q3 FY2027 | $0.0B | $0.0B | $0.0B | 0 |
Earnings Price Reaction
Closing price one trading day before vs. one trading day after each earnings release.
| Period | Report Date | EPS Beat/Miss | Price Before | Price After | 1D Reaction |
|---|---|---|---|---|---|
| ▼ Q2 FY2026 | May 14, 2026 | -412.8% | $2.31 | $2.34 | +1.30% |
| ▼ Q1 FY2026 | Feb 24, 2026 | -41.4% | $3.72 | $3.90 | +4.84% |
| ▼ Q4 FY2025 | Nov 12, 2025 | -384.1% | $1.96 | $1.80 | -8.16% |
| ▼ Q3 FY2025 | Aug 13, 2025 | -33.9% | $9.72 | $10.13 | +4.22% |
| ▼ Q2 FY2025 | May 13, 2025 | -440.1% | $6.00 | $6.18 | +3.00% |
| ▼ Q1 FY2025 | Mar 3, 2025 | -167.9% | $6.42 | $6.00 | -6.54% |
| ▲ Q4 FY2024 | Nov 12, 2024 | +55.8% | $7.44 | $7.02 | -5.65% |
| ▲ Q3 FY2024 | Aug 13, 2024 | +5.5% | $7.56 | $7.80 | +3.17% |
Q2 FY2026+1.30%
Report Date
May 14, 2026
EPS Beat/Miss
-412.8%
Price Before
$2.31
Price After
$2.34
Q1 FY2026+4.84%
Report Date
Feb 24, 2026
EPS Beat/Miss
-41.4%
Price Before
$3.72
Price After
$3.90
Q4 FY2025-8.16%
Report Date
Nov 12, 2025
EPS Beat/Miss
-384.1%
Price Before
$1.96
Price After
$1.80
Q3 FY2025+4.22%
Report Date
Aug 13, 2025
EPS Beat/Miss
-33.9%
Price Before
$9.72
Price After
$10.13
Q2 FY2025+3.00%
Report Date
May 13, 2025
EPS Beat/Miss
-440.1%
Price Before
$6.00
Price After
$6.18
Q1 FY2025-6.54%
Report Date
Mar 3, 2025
EPS Beat/Miss
-167.9%
Price Before
$6.42
Price After
$6.00
Q4 FY2024-5.65%
Report Date
Nov 12, 2024
EPS Beat/Miss
+55.8%
Price Before
$7.44
Price After
$7.02
Q3 FY2024+3.17%
Report Date
Aug 13, 2024
EPS Beat/Miss
+5.5%
Price Before
$7.56
Price After
$7.80
Avg Beat Reaction-1.24%
Avg Miss Reaction-0.22%
Beat Rate2 / 8 quarters
Largest Move-8.16% (Q4 FY2025)
Data: FMP /historical-price-eod/full · field: close
About Earnings & Data Methodology
Data source: Financial Modeling Prep (FMP) | Updated: Hourly | Surprise%: (Actual − Estimate) / |Estimate| × 100 | Fiscal year: ARTL ends December
Artelo Biosciences, Inc. (ARTL) most recently reported earnings on May 14, 2026 for Q2 FY2026, posting EPS of $-4.00 — missing the analyst consensus of $-0.78 by -412.8%. The next ARTL earnings date is expected around September 1, 2026.
Each quarter, investors track ARTL earnings for signals on forward guidance and business momentum. For longer-term revenue trends, see the Revenue tab. ARTL revenue tab →
Earnings Glossary
EPS (Earnings Per Share)
Net income ÷ diluted shares outstanding. The primary metric analysts use to gauge quarterly profitability.
Earnings Surprise %
(Actual − Estimate) / |Estimate| × 100. Positive = Beat. Negative = Miss.
Beat / Miss / In-Line
Beat = Actual ≥ Estimate. Miss = Actual < Estimate. In-Line = within ±1%.
BMO / AMC
Before Market Open / After Market Close. Two windows when companies typically release results.
Fiscal Quarter
ARTL's fiscal year ends in December. Fiscal quarters may not align with calendar quarters.
Analyst Consensus
Average EPS/Revenue forecast across all covering analysts. More analysts = more reliable estimate.
Figures tie to FMP earnings calendar, estimates, and SEC 10-Q/10-K filings where noted.
Frequently asked questions
ARTL earnings · 5 questionsArtelo Biosciences, Inc.'s next earnings report is expected around September 1, 2026. ARTL typically reports quarterly — approximately every three months. The exact date is confirmed by the company 2–4 weeks before the release. Time is currently TBD; ARTL historically reports after market close (AMC).
ARTL earnings datewhen is ARTL earningsARTL next earnings datewhen does ARTL report earningsARTL earnings calendar
▸ Source: FMP · Artelo Biosciences, Inc. SEC filings · US GAAP · Artelo Biosciences, Inc. SEC 10-K & 10-Q filings · US GAAP · Updated: Jun 8, 2026